Qualitative Study on the Acceptability of and Adherence to a Vaginal Ring for HIV Prophylaxis Among Adolescent Girls.
Journal
Journal of acquired immune deficiency syndromes (1999)
ISSN: 1944-7884
Titre abrégé: J Acquir Immune Defic Syndr
Pays: United States
ID NLM: 100892005
Informations de publication
Date de publication:
01 07 2021
01 07 2021
Historique:
received:
14
09
2020
accepted:
30
12
2020
pubmed:
7
3
2021
medline:
8
10
2021
entrez:
6
3
2021
Statut:
ppublish
Résumé
This study aims to assess the product-related, relationship-related, and sex-related factors that act as facilitators and barriers to the acceptability of a vaginal ring (VR) for HIV prevention among adolescent girls. Qualitative study. Ninety-six girls aged 15-17 years from 6 urban US sites were enrolled in MTN-023/IPM 030, a 24-week randomized controlled trial, for assessing the safety and acceptability of a dapivirine VR for HIV prevention. At week 24, 21 girls were randomly selected to participate in in-depth interviews. Interviews were transcribed verbatim and data analyzed using a thematic analysis approach. Facilitators and barriers to VR acceptability related to participants' relationships, sexual activity, and characteristics of the VR product were identified. Factors related to relationships rarely seemed to act as barriers to VR acceptability; most participants disclosed VR use to sexual partners, and positive reactions from sexual partners, which were common, seemed to facilitate VR acceptability. Emotional and/or physical discomfort surrounding VR use during sex was mentioned occasionally as a barrier to VR acceptability. Product characteristics were most frequently mentioned as barriers to VR acceptability. Many participants reported concerns about the large size of the VR on first impression. Although most found the VR comfortable, some reported pain with VR insertion. Several participants were concerned about VR cleanliness, particularly during menstruation. Product considerations, specifically size and use during menstruation, were the most commonly reported barriers to VR acceptability in this study. Adolescent girls may require additional counseling to assuage product concerns regarding a VR for HIV prevention.
Identifiants
pubmed: 33675614
doi: 10.1097/QAI.0000000000002674
pii: 00126334-202107010-00010
pmc: PMC8192420
mid: NIHMS1677489
doi:
Substances chimiques
Anti-HIV Agents
0
Types de publication
Journal Article
Multicenter Study
Randomized Controlled Trial
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
944-950Subventions
Organisme : NIAID NIH HHS
ID : UM1 AI068633
Pays : United States
Organisme : NIAID NIH HHS
ID : UM1 AI068615
Pays : United States
Organisme : NIAID NIH HHS
ID : UM1 AI106707
Pays : United States
Organisme : NIAID NIH HHS
ID : P30 AI060354
Pays : United States
Organisme : NIAID NIH HHS
ID : UM1 AI069536
Pays : United States
Informations de copyright
Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.
Déclaration de conflit d'intérêts
The authors have no conflicts of interest to disclose.
Références
Celum C, Delany-Moretlwe S, McConnell M, et al. Rethinking HIV prevention to prepare for oral PrEP implementation for young African women. J Int AIDS Soc. 2015;18:20227.
Singh J. Why vulnerable young women at risk of HIV should be prioritized for access to preexposure prophylaxis. AIDS. 2013;27:1998–1999.
UNAIDS. UNAIDS Data 2020. Geneva, Switzerland; 2016. Available at: https://www.unaids.org/sites/default/files/media_asset/2020_aids-data-book_en.pdf . Accessed October 29, 2019.
Case K, Ghys P, Gouws E, et al. Understanding the modes of transmission model of new HIV infection and its use in prevention planning. World Health Organ. 2012;90:831–838A.
Dellar R, Dlamini S, Karim Q. Adolescent girls and young women: key populations for HIV epidemic control. J Int AIDS Soc. 2015;18(2 suppl 1):19408.
Pomerantz R, de la Monte S, Donegan S, et al. Human immunodeficiency virus (HIV) infection of the uterine cervix. Ann Intern Med. 1988;108:321–327.
Nagelkerke N, Moses S, de Vlas S, et al. Modelling the public health impact of male circumcision for HIV prevention in high prevalence areas in Africa. BMC Infect Dis. 2007;7:16.
Rosenthal S, Cohen S, Stanberry L. Topical microbicides. Current status and research considerations for adolescent girls. Sex Transm Dis. 1998;25:368–377.
Shannon K, Leiter K, Phaladze N, et al. Gender inequity norms are associated with increased male-perpetrated rape and sexual risks for HIV infection in Botswana and Swaziland. PLoS One. 2012;7:e28739.
Idele P, Gillespie A, Porth T, et al. Epidemiology of HIV and AIDS among adolescents: current status, inequities, and data gaps. J Acquir Immune Defic Syndr. 2014;66(suppl 2):S144–S153.
Maughan-Brown B, Kenyon C, Lurie M. Partner age differences and concurrency in South Africa: implications for HIV-infection risk among young women. AIDS Behav. 2014;18:2469–2476.
Marrazzo JM, Ramjee G, Richardson BA, et al. Tenofovir-based preexposure prophylaxis for HIV infection among African women. N Eng J Med. 2015;372:509–518.
Van Damme L, Corneli A, Ahmed K, et al. Preexposure prophylaxis for HIV infection among African women. N Eng J Med. 2012;367:411–422.
Abdool Karim Q, Abdool Karim SS, Frohlich JA, et al. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science. 2011;329:1168–1174.
Corneli AL, Deese J, Wang M, et al. FEM-PrEP: adherence patterns and factors associated with adherence to a daily oral study product for pre-exposure prophylaxis. J Acquir Immune Defic Syndr. 2014;66:324–331.
Chen BA, Panther L, Marzinke MA, et al. Phase 1 safety, pharmacokinetics, and pharmacodynamics of dapivirine and maraviroc vaginal rings: a double-blind randomized trial. J Aacquir Immune Defic Syndr. 2015;70:242–249.
Baeten J, Palanee-Phillips T, Brown E, et al. Use of a vaginal ring containing dapivirine for HIV-1 prevention in women. N Engl J Med. 2016;375:2121–2132.
Mensch B, Richardson B, Husnik M, et al. Vaginal ring use in a phase 3 microbicide trial: a comparison of objective measures and self-reports of non-adherence in ASPIRE. AIDS Behav. 2019;23:504–512.
Nel A, van Niekerk N, Kapiga S, et al. Safety and efficacy of a dapivirine vaginal ring for HIV prevention in women. NEJM. 2016;375:2133–2143.
Bunge K, Levy L, Szydlo D, et al. Brief report: phase IIa safety study of a vaginal ring containing dapivirine in adolescent young women. J Acquir Immune Defic Syndr. 2020;83:135–129.
Sahin-Hodoglugil N, Montgomery E, Kacanek D, et al. User experiences and acceptability attributes of the diaphragm and lubricant gel in an HIV prevention trial in southern Africa. AIDS Care. 2011;23:1026–1034.
Severy L, Tolley E, Woodsong C, et al. A framework for examining the sustained acceptability of microbicides. AIDS Behav. 2005;9:121–131.
Crosby R, DiClemente R, Wingood G, et al. Correlates of unprotected vaginal sex among African American female adolescents: importance of relationship dynamics. Arch Pediatr Adolesc Med. 2000;154:893–899.
Laborde N, Pleasants E, Reddy K, et al. Impact of the dapivirine vaginal ring on sexual experiences and intimate partnerships of women in an HIV prevention clinical trial: managing ring detection and hot sex. AIDS Behav. 2018:437–446.
MacPhail C, Campbell C. 'I think condoms are good but, aai, I hate those things': condom use among adolescents and young people in a Southern African township. Soc Sci Med. 2001;52:1613–1627.
Poulin M. Sex, money, and premarital partnerships in southern Malawi. Soc Sci Med. 2007;65:2383–2393.
Gage AJ. Sexual activity and contraceptive use: the components of the decisionmaking process. Stud Fam Plann. 1998;29:154–166.
Selikow T, Ahmed N, Flisher A, et al. I am not “umqwayito”: a qualitative study of peer pressure and sexual risk behaviour among young adolescents in Cape Town, South Africa. Scand J Public Health. 2009;37(suppl 2):107–112.
Montgomery E, van der Straten A, Chitukuta M, et al. Acceptability and use of a dapiviring vaginal ring in a phase III trial. AIDS. 2017;31:1159–1167.
Naidoo K, Mansoor LE, Katz AW, et al. Qualitative perceptions of dapivirine vaginal ring adherence and drug level feedback following an open-label extension trial. J Acquir Immune Defic Syndr. 2021;86:e90–e96.
Carballo-Dieguez A, Giguere R, Dolezal C, et al. Tell Juliana: acceptability of the candidate microbicide VivaGel(R) and two placebo gels among ethnically diverse, sexually active young women participating in a phase 1 microbicide study. AIDS Behav. 2012;16:1761–1774.